Parthenogenetic embryonic stem cells (pESCs) derived from artificially activated oocytes without fertilization presumably raise minimal ethical concerns and may serve as attractive candidates for regenerative medicine. Here we investigated whether pESCs could repair myocardial infarction (MI), in comparison to embryonic stem cells (ESCs).
Introduction
Myocardial infarction (MI) is one of the leading causes of morbidity and mortality in the world. 1 Recent advances in stem cell biology have brought great hope for the development novel therapeutic strategies, such as stem cell transplantation to hearts post-MI as an effective approach. 2 In the past decades, transplantation of adult stem cells, including haematopoietic stem cells 3 and mesenchymal stem cells, 4, 5 proved beneficial for MI. Early studies demonstrated that haematopoietic stem cells and mesenchymal stem cells could differentiate into cardiomyocytes in ischaemic myocardium. 3, 4 However, follow-up studies challenged this transdifferentiation mechanism, 6 and suggested that the expression of cardiac markers was most likely to be a result of cell fusion. 7 Nowadays, the majority of investigators tend to attribute the functional improvements produced by adult stem cells to a paracrine action stimulating angiogenesis and cardiomyocyte survival. 8, 9 Embryonic stem cells (ESCs) are a promising cell source for myocardial regeneration owing to their high pluripotency and differentiation capacity, both in vitro 10 and in vivo. 11 The germline competency made ESCs a hot topic, and the establishment of a human ESC cell line brought enormous prospects in cardiac regeneration research. However, ethical concerns, the possibility of immunological rejection, and the propensity for teratoma formation by ESCs may restrict their potential clinical applications. 12 The recent breakthrough in inducible pluripotent stem cell research has revitalized stem cell therapy. However, the low reprogramming efficiency, heterogeneity in pluripotency, and teratoma formation remain major challenges for the application of inducible pluripotent stem cells. 13 -15 In addition, a recent study has also reported that inducible pluripotent stem cells derived from immature autologous cells showed immunogenicity even in a syngenic transplantation. 16 pESCs provide an alternative source for ESCs without using fertilized eggs and could avoid the ethical controversy and reduce cell immunogenicity. 17 pESCs can be generated efficiently from parthenogenetic blastocysts derived from artificially activated unfertilized oocytes without destroying a live embryo, and are therefore regarded as ethically acceptable cell sources. A pESC cell line was first isolated by Kaufman et al. in 1983 from mice, 18 and then by others from primates 19 and humans. 20 Although concerns exist about possible drawbacks of aberrant genomic imprinting and some paternal gene expression in pESCs, 21 we and others showed appropriate expression of paternally imprinted genes and high developmental pluripotency of newly established pESCs in mice. 22 -24 pESCs can be induced to differentiate in vitro into cells from all three germ layers, including cardiomyocytes and endothelial cells, and are able to form muscle-like tissue in vivo. 17, 25 Recently, we have successfully produced live parthenote pups from pESCs through tetraploid embryo complementation, suggesting that pESCs can undergo full-term development and differentiate into all cell types and functional organs. 22, 23 Moreover, pESCs provide a source of histocompatible tissues for transplantation. 17 Taken together, the self-renewal capacity, myogenic differentiation potential, and low immunogenicity make pESCs a promising cell source for regenerative therapy. Direct transplantation of undifferentiated ESCs or inducible pluripotent stem cells was associated with teratoma formation. 12, 26 The potential safety issues of pESCs have not yet been rigorously evaluated. We have previously evaluated the therapeutic effects of mesenchymal stem cells and granulocyte colony-stimulating factor on cardiac remodelling following MI. 27, 28 In the present study, we hypothesized that pESCs would repair the ischaemic myocardium. We investigated the cardiac repair capacity and tumourigenecity of pESCs, in comparison to ESCs, delivered by intramyocardial injection in a mouse model of acute MI.
Methods
For more experimental details, please refer to the Supplementary material online.
Animals
Adult female C57BL/6 and male C3H mice (8 -10 weeks old, weighing 22 -25 g) were purchased from the Laboratory 
Cell labelling
pESC and ESC cell lines were isolated from parthenogenetic and fertilized embryos of B6C3F1 hybrid mice, respectively, as previously described. 22, 23 Prior to transplantation, cells were labelled with DiI, a red fluorescent dye that labels the cell membrane and can be used for cell tracking (Molecular Probes, Eugene, OR, USA), filtered and resuspended in normal saline at 1.0 × 10 7 cells/mL. DiI labelling had no effect on cell morphology, viability, or proliferation capacity. The labelled cells maintained the fluorescence signal for more than 1 month. 27 
Surgical procedures and cell transplantation
Myocardial infarction was induced in adult B6C3F1 hybrid mice (9 -11 weeks old, weighing 25-30 g; n ¼ 89). Briefly, mice were anaesthetized through inhalation of isoflurane (1 -1.5%) in O 2 , followed by intubation and mechanical ventilation using an anaesthetic machine (Hallowell EMC MicroVent 1, Pittsfield, MA, USA). After the mice entered a relaxed state without breath depression and dysphoria, the left anterior descending coronary artery was permanently ligated using a 7 -0 silk suture via a left thoracotomy at the fourth intercostal space. Infarction was considered successful following the visual appearance of pale discolouration and an ST elevation on electrocardiograms. Immediately after the ligation, mice randomly received 2.0 × 10 5 DiI-labelled pESCs, ESCs or saline in 20 mL by two injections were given into two areas adjacent to the infarcted tissue with a 30-gauge needle ( Figure 1A) . Afterwards, the chest wall and skin were closed. During the operation, the heart rate, respiratory rate, blood pressure, and body temperature of the mice were carefully monitored. The level of anaesthesia (end-tidal concentration of isoflurane 1 -2%) was adjusted according to the surgical stimulation, by monitoring signs of movement and changes in the heart rate, respiratory rate, and blood pressure. As soon as the anaesthesia was stopped, the animals woke up immediately (normally in about 1 -2 min). Sham operations were performed on another 21 mice without left anterior descending coronary artery occlusion. Three time points (7, 14 and 30 days) were included, and the groups and numbers of the mice are listed in the Supplementary material online, Table S1 . At each time point, mice were killed by cervical dislocation, and heart samples were harvested for corresponding analyses. In another separate study, mice with MI, treated with pESCs (n ¼ 14) or saline (n ¼ 17), were followed for up to 90 days for heart function and histological assessment to determine the long-term effect of pESCs.
Quantitative real-time polymerase chain reaction analysis of pro-angiogenic cytokines
Heart samples ( Figure 1A ) from day 7 were analysed by quantitative realtime polymerase chain reaction (qPCR). Total RNA was extracted with TranZol Reagent (TransGen Biotechnology, Beijing, China). The qPCRs were performed in triplicate with the FastStart Universal SYBR Green Master (ROX; Roche, Mannheim, Germany) and run on the iCycler iQ5 2.0 Standard Edition Optical System (Bio-Rad, Hercules, CA, USA). Pro-angiogenic cytokines, including vascular endothelial growth factor a (VEGFa), basic fibroblast growth factor (bFGF; also termed FGF2), and insulin-like growth factor-1 (IGF-1) were estimated against the housekeeping gene GAPDH. Primers for VEGFa, bFGF, and GAPDH were used as previously reported. 29 IGF-1 primers (Supplementary material online, Table S2 ) were designed using Primer Premier 5.0 software (Premier Biosoft International, Palo Alto, Canada).
Enzyme-linked immunosorbent assay
Peripheral blood samples (n ¼ 19) collected on day 7 before the mice were killed were analysed for the levels of VEGF, bFGF, and IGF-1 using commercially available enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's protocol (RB, Camarillo, CA, USA).
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Histomorphological analysis
Heart samples were fixed with Carnoy's fixative solution, embedded in paraffin, and cut into 5-mm-thick sections. Five consecutive sections at 100 mm intervals were stained with haematoxylin and eosin for histology, with Masson's staining for collagen. The lengths of the infarction surfaces, involving both epicardial and endocardial regions, and the area of collagen deposition were measured using Image-Pro Plus software (version 6.0; Media Cybernetics, Silver Spring, MD, USA) and averaged. The infarct size and collagen content were determined as a percentage of the total left ventricular (LV; including interventricular septum) circumference or area. The area of the infarct was determined following an approach similar to the one used in our previous report. 27 
Immunological analysis
To determine the leucocyte infiltration, thin paraffin sections were incubated with primary antibody against CD45 (BD, Franklin Lakes, NJ, USA), and then with Alexa Fluor 488 goat anti-rat immunoglobulin G (IgG; Molecular Probes). Images of eight randomly selected fields were captured using an advanced fluorescence microscope (Zeiss, Oberkochen, Germany). The CD45-positive cells were counted and expressed as CD45 + cells per high power field (HPF; ×400). Cell nuclei were stained with 4 ′ ,6-diamidino-2-phenylindole (DAPI; Sigma, Milwaukee, WI, USA).
To determine cell differentiation, sections were immunostained with antibodies against von Willebrand factor (vWF; Dako, Glostrup, Denmark) for endothelial cells, a-smooth muscle actin (a-SMA; Boster Biotechnology, Wuhan, China) for smooth muscle cells, and the specific cardiac marker 30 To determine angiogenesis, thin sections were stained with vWF and isolectin-IB4 conjugated with Alexa Fluor 488 (Molecular Probes). The numbers of blood vessels and capillaries in the ischaemic myocardium were determined as vessels/HPF (×200) or capillaries/HPF (×400). Cardiomyocyte hypertrophy was assessed by staining the sections with Alexa Fluor 488 conjugated wheat germ agglutinin (Molecular Probes; 10 mg/mL). The transverse area of cardiomyocytes (150 cells per heart) was determined using ImageJ software (Provided by National Institutes of Health).
Echocardiographic examination
Mice (n ¼ 30) were anaesthetized with 2% chloral hydrate (320 mg/kg, i.p.) and examined using a VisualSONICS echocardiographic system equipped with a 30 MHz transducer (RMV-707B; Toronto, Canada) 30 days post-MI. Heart function indices were calculated using the Vevo 770 V3.0.0 Software (VisualSonics Inc., Toronto, Canada). The limb leads electrocardiogram (ECG) were also recorded, and the corresponding PR and QRS intervals of each group were measured and analysed based on the ECG records of at least 100 beats.
Statistical analysis
All data are presented as means + SEM. An independent t-test was used for two-group comparisons, and one-way ANOVA for multiple-group comparisons, with suitable post hoc analysis. A P-value of ,0.05 was considered statistically significant.
Results

Transplantation of pESCs enhanced the expression of pro-angiogenic cytokines and reduced leucocyte infiltration
Gene expression of VEGFa, bFGF, and IGF-1 in hearts post-MI at day 7 was determined using qPCR. Three cytokines showed increased mRNA expression following MI and cell transplantation, and expression levels in MI hearts treated with pESCs were slightly higher than those of the ESC-treated group ( Figure 1B) . However, protein levels of these factors in peripheral blood measured by ELISA did not differ among the groups ( Figure 1C) .
Leucocyte infiltration into the damaged myocardium post-MI is an indicator of inflammation. 31, 32 Transplantation of pESCs or ESCs significantly reduced leucocyte infiltration in comparison to salinetreated hearts, as evidenced by a reduction in the number of CD45 + cells ( Figure 1D) , suggesting an attenuation of inflammatory response and improvement of the infarct microenvironment by stem cell treatment.
Grafted pESCs and ESCs differentiated into cardiac-and vascular-like cells in ischaemic myocardium
To determine the differentiation capability of the transplanted cells, sections were immunostained with the cardiac marker TnT, and vascular markers vWF and a-SMA. DiI-labelled cells were observed mainly in the infarct area (Supplementary material online, Figure S3A ) and were also positive for TnT (Figure 2A) , indicating their commitment to the cardiogenic lineage. Such differentiation was constantly observed for the entire experimental period up to 90 days (Supplementary material online, Figure S7A ). Differentiation of the transplanted cells towards endothelial cells was also observed at 30 days post-MI. DiI + vWF + cells were typically found in the luminal surface of blood vessels, especially those with a diameter larger than 50 mm, in the infarct region ( Figure 2B ). This result suggests the participation of the implanted cells in repair or replacement of damaged or lost endothelial cells. DiI + a-SMA + cells were also found in the media layer. These cells were mainly located in the border or infarct area with dense vessels, suggesting their involvement in angiogenesis ( Figure 2C ). did not show significant differences between the ESC and the pESC group (data not shown), indicating ESCs and pESCs had a similar capacity for differentiation in the ischaemic myocardium.
Treatment with pESCs improved left ventricular function
Thirty days after cell transplantation, LV dimensions were evaluated using echocardiography (Supplementary material online, Figure S4 ). Compared with the sham group, all infarcted mice displayed a decrease in LV anterior wall thickness and heart function ( Figure 3) . Transplantation with pESCs significantly increased LV anterior wall end-diastolic thickness (LVAWd) and LV anterior wall end-systolic thickness (LVAWs) compared with the ESC and saline groups ( Figure 3A and B) . pESCs also reduced LV end-diastolic diameter (LVEDd) and LV end-systolic diameter (LVEDs) of hearts post-MI ( Figure 3C and D) . Transplantation of either pESCs or ESCs remarkably improved LV contractile function as defined by ejection fraction (EF) and fractional shortening (FS; Figure 3E and F ). Improved heart function was likewise observed in pESC-treated mice compared with the saline group during longer-term investigation (i.e. 90 days; Supplementary material online, Figure S6 ). Stem cell transplantation may increase the incidence of ventricular arrhythmias. 33 Our data show that injection of pESCs or ESCs did not cause arrhythmia (Supplementary material online, Figure S4) . Analysis of the QRS interval, which is indicative of the ventricular depolarization dynamics, suggested the establishment of an appropriate MI model.
Transplantation with pESCs reduced collagen deposition and prevented cardiac hypertrophic remodelling
A distinct collagen scar and chamber enlargement could be observed in all mice post-MI by histological staining. Consistent with the echocardiography data, all infarcted mice showed a markedly thin anterior wall and dilatation of the LV chamber ( Figure 4A ). Transplantation of ESCs or pESCs decreased the content of collagen in comparison with the saline group ( Figure 4B) . The heart/body weight ratio at 30 days post-MI was significantly higher than for sham-operated animals because of cardiac remodelling, while stem cell transplantation slightly attenuated this phenomenon ( Figure 4C ). We also calculated the infarct size based on five haematoxylin-and eosin-stained sections, and found that the infarction was reduced to some extent, and the effect was comparable between the ESC and the pESC group (data not shown). Moreover, histological analysis at day 90 showed significantly decreased infarction and collagen content in the group treated with pESCs (Supplementary material online, Figure S8 ). Cardiac hypertrophy was analysed by wheat germ agglutinin staining. The transverse area of myocytes increased dramatically in all mice 30 days post-MI, while transplantation of pESCs effectively attenuated the myocyte hypertrophy compared with the saline group ( Figure 4D and E). These data suggest that engraftment of pESCs maintains the LV geometry well, and reduces the adverse ventricular remodelling.
Transplantation with pESCs increased blood vessel and capillary density
Neovascularization in the ischaemic myocardium was assessed by vWF immunostaining 14 and 30 days following cell transplantation ( Figure 5A) . Compared with the saline group, both pESCs and ESCs increased the vessel density about two-fold in the treated hearts at the early time point (14 days), while vessel density in pESC-treated group was much higher than that of ESC-treated group at day 30 (P , 0.01, Figure 5B ). An independent experiment was performed to investigate the long-term (90 days) effects of treatment with pESCs. The results showed that pESC-induced neovascularization remained up to 90 days following transplantation (Supplementary material online, Figure S7B ). Capillaries in the infarct and border region were examined by isolectin staining. The capillary density in the ESC-and pESC-treated hearts was significantly higher than that in the the saline and sham groups at both 14 and 30 days ( Figure 5C and D).
Transplantation with pESCs caused no teratoma formation within 30 days
Undifferentiated ESCs generate teratomas upon implantation. 12 Indeed, animals treated with ESCs showed teratoma formation adjacent to the LV anterior wall at days 14 and 30 ( Figure 6A and B) .
The tumours were composed of various types of cells derived from at least two germ layers ( Figure 6A and B) . Intra-myocardial teratomas were also found at day 30 in the ESC-treated group, and contained, in particular, transformed epidermis and other structures derived from endoderm and ectoderm (Supplementary material online, Figure  S5A ). In contrast, no teratomas were found in pESC-treated mice ( Figure 6C and D) . Only one small 'cyst', consisting of simple cuboidal epithelium, was found in one pESC-treated mouse at day 30 (Supplementary material online, Figure S5B ). The total incidence of teratoma formation is shown in Figure 6D and the Supplementary material online, Table S1 . In the extended study (90 days), only 2 of 14 pESC-treated hearts showed teratoma development (Supplementary material online, Figure S9 ). However, the ESC treatment group was not included in the long-term study, and thus no comparison could be made between the two stem cell treatment groups. Teratoma was observed as early as 14 days in ESC-treated group, while it was not found until 90 days at reduced rates in the pESC-treated group, suggesting that teratoma generation is significantly reduced or delayed by transplantation of pESCs.
Discussion
Parthenogenetic embryonic stem cells have been suggested as a promising cell source candidate in regenerative medicine. 17 It remains unclear whether or not pESCs could repair the damaged heart following MI. Here we show that transplantation of pESCs into the ischaemic myocardium significantly enhances neovascularization, improves heart function, and effectively preventes cardiac remodelling. Moreover, engrafted pESCs exhibit differentiation in damaged heart without teratoma formation up to 30 days. It is widely accepted that the adult mammalian heart is a terminally differentiated organ with minimal regenerative capacity. 34 After MI, dead myocytes are replaced by fibrotic scar tissues, which cause irreversible contractile dysfunction. 35 Although regeneration of new myocytes does take place following injury via direct division of autologous cardiomyocytes 36 and differentiation from endogenous cardiac progenitor cells, 37 they are still insufficient to compensate for the severe loss of functional cardiomyocytes. Recent studies indicate that stem cell transplantation may be a promising strategy for myocardial regeneration upon ischaemic infarction. Our study demonstrates that the transplanted pESCs are positive for the cardiac marker TnT, suggesting their cardiac differentiation in the ischaemic myocardium. Previously, ESCs have been shown to exhibit cardioprotection by paracrine secretion. 38 We showed by qPCR that transplantation of pESCs increased mRNA levels of VEGFa, bFGF, and IGF-1 in the localized myocardium. These factors are known for their pro-angiogenic effects to stimulate neovascularization. 39, 40 We also found an increase in vascular density in the stem cell-treated hearts by immunostaining ( Figure 5 ). Improved microcirculation could better supply nutrition and oxygen, and attenuate the ischaemic injury. In addition, transplantation of stem cells also reduced the inflammatory response, as indicated by a lower leucocyte infiltration ( Figure 1D , Supplementary material online, Figure S2A ), which is beneficial for cardiomyocyte survival and recovery from damage. 31 It was also found that the transplanted pESCs or ESCs could differentiate into cardiac-like cells, endothelial cells, and smooth muscle cells (Figure 2 ). In addition, transplantation of ESCs or pESCs significantly increased the number of proliferating cells in Parthenogenetic stem cells repair heart infarction both border and infarct areas 7 days post-MI (Supplementary material online, Figure S2B ). However, the definition of cell types and the mechanisms by which their proliferation can be activated require further investigation. ESCs are immunologically privileged because of low expression of membrane antigens. 41, 42 Transplantation of undifferentiated mouse
ESCs into infarcted hearts of immunocompetent rats led to functional improvement and integration of ESC-derived cardiomyocytes with the resident myocytes. 11, 42 No evidence of graft rejection or tumour formation was observed in those studies up to 12 weeks. 11, 42 Likewise, in the present study we did not observe obvious immuno-rejection stimulated by implanted pESCs and ESCs. For instance, the transplanted DiI-labelled pESCs or ESCs were still observed 90 days after transplantation ( Figure 2 and Supplementary material online, Figure S3 ). The issue of teratoma formation always undermines the possible therapeutic application of ESCs. 2, 12 Transplantation of undifferentiated ESCs caused cardiac teratoma formation, 43 which could be prevented by guided differentiation of ESCs to myocardial cells using cytokines. 44, 45 In agreement with a previous report, 43 teratoma formation by implanted ESCs was confirmed in our study ( Figure 6 ). By 30 days, teratomas were found in ESC-treated animals at a relatively high rate (6 of 34; 17.65%). In contrast, only one small 'cyst', consisting of simple cuboidal epithelium, was observed in a pESC-treated heart from one mouse. We also noted that transplantation of undifferentiated pESCs may not be absolutely safe, because in the long-term study (90 days) two cases of teratoma formation were observed in the pESC group (Supplementary material online, Figure  S9 ). Comparatively, engraftment of pESCs was relatively safer than engraftment of ESCs in the present study (pESCs, 2 of 44 at 90 days vs. ESCs, 6 of 34 at 30 days). The low tumourigenicity of pESCs might partly be related to their lower expression level of c-myc (Supplementary material online, Figure S1B ), whose constitutive activation and expression is key to the genesis of many cancers. 46, 47 As yet, the underlying mechanism remains to be determined. Overall, engraftment of pESCs significantly improved cardiac function, and reduced the size of the infarct and the deposition of collagen compared with the saline group. However, transplantation of pESCs did not fully restore cardiac function post-MI. Further optimization of the therapeutic protocol would be beneficial in order to improve the treatment outcome, for instance, by induction of differentiation, genetic modification, and modulation of the local microenvironment by the incorporation of growth factors or other niches to the transplanted cells in order to enhance the cardiogenic and angiogenic properties of the pESCs. Despite the low tumourigenesis of pESCs, the oncogenic risk of using this strategy still remains, and further investigation is needed prior to any clinical application.
In conclusion, transplantation of pESCs improved cardiac performance owing to their capacity to differentiate into myocardial cells and to enhance neovascularization. The therapeutic effect of pESCs was comparable to that of ESCs. However, the incidence of teratoma formation in the pESC-treated group was much lower compared with the ESC-treated group, suggesting that pESCs may provide safer sources for treatment of myocardial infarction. Additional studies are needed in order to understand the mechanisms underlying the myocardial regeneration and neovascularization stimulated by pESCs and to improve their therapeutic efficacy.
